Updated

Viking Therapeutics' stock surged after a clinical trial showed its GLP-1/GIP drug candidate VK2735 helped patients maintain weight loss, including those on a once-monthly dosing schedule, positioning it as a potential competitor to Eli Lilly's Zepbound. The results add Viking to the list of companies challenging established players in the increasingly competitive obesity-drug market.